The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
BioSeeker Group AB
November 22, 2005 SKU: BIOS1191164
|
|
Executive Summary
Full Title: The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
Introduction
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics.
Scope of this report
- Thorough examination of the top eight cancer therapeutic antibodies on the market.
- The race towards the next generation of therapeutic antibodies and improved drug delivery methods there of.
- Antibody deals are on the rise, where of those targeting oncology is the single most active area.
- Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Research and analysis highlights
The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.
Key reasons to read this report
- One source to the top cancer therapeutic antibodies on the market.
- Key insights into the second wave in the lucrative field of therapeutic antibodies.
- Competitive landscape assessment, including deals, technologies and more than 100 companies in the field and close to 100 cancer therapeutic antibodies.
|
- 1. Executive Summary
- 2 Cancer Highlights
- 3 Methodology
- 4 4.1 List of Boxes
- 4.2 List of Tables
- 5 Key Developmental Strategies
- 6 Treating Colorectal Cancer
- 6.1 Avastin
- 6.1.1 Avastin -Major Developmental Milestones
- 6.1.2 Sales Predictions on Avastin
- 6.1.3 Avastin Related Studies
- 6.2 Erbitux
- 6.2.1 Erbitux -Major Developmental Milestones
- 6.2.2 Sales Predictions on Erbitux
- 6.2.3 Erbitux Related Studies
- 7 Treating Lymphomas
- 7.1 Rituxan
- 7.1.1 Sales Predictions on Rituxan
- 7.1.2 Rituxan -Major Developmental Milestones
- 7.1.3 Rituxan Related Studies
- 7.2 Bexxar
- 7.2.1 Sales Predictions on Bexxar
- 7.2.2 Bexxar -Major Developmental Milestones
- 7.2.3 Bexxar Related Studies
- 7.3 Zevalin
- 7.3.1 Sales Predictions on Zevalin
- 7.3.2 Zevalin -Major Developmental Milestones
- 7.3.3 Zevalin Related Studies
- 8 Treating Leukemias
- 8.1 ALL
- 8.2 CLL
- 8.3 AML
- 8.4 CML
- 8.5 Campath
- 8.5.1 Campath -Major Developmental Milestones
- 8.5.2 Campath Related Studies
- 8.6 Mylotarg
- 8.6.1 Mylotarg Related Studies
- 9 Treating Lung cancer
- 9.1 Cotara
- 10 Antibody Deals on the Rise
- 10.1 Antibody Deals in Phase III
- 10.1.1 Deal Situation: MDX 010
- 10.1.2 Deal Situation: WX G250
- 10.1.3 Deal Situation: Zanolimumab
- 10.2 Antibody Deals in Phase II
- 10.2.1 Deal Situation: Mapatumumab
- 10.2.2 Deal Situation: GCR 3888
- 10.2.3 Deal Situation: MDX 070
- 10.2.4 Deal Situation: CDP 860
- 10.2.5 Deal Situation: Tru-Scint OV
- 10.2.6 Deal Situation: SC 1
- 10.2.7 Deal Situation: PRO 70769
- 10.2.8 Deal Situation: XR 303
- 10.2.9 Deal Situation: HumaRAD-HN
- 11 New Approaches in Antibody Delivery and Design The Next Generation
- 11.1 How to Make Them Smaller and Different?
- 11.2 Biomaterials in Sustained Delivery Applications
- 11.2.1 Implants
- 11.3 Gene delivery the Future?
- 11.3.1 Delivery Vehicles for DNA
- 11.3.2 Gene Delivery in Commercialization
- 12 Current Analysis of Mabs in Clinical Development
- 12.1.1 Prostate Cancer Therapeutics
- 12.1.2 Breast Cancer Therapeutics
- 12.1.3 Colorectal Cancer Therapeutics
- 12.1.4 Melanoma Therapeutics
- 12.1.5 Hematological Cancers Therapeutics
- 12.2 Mabs in Late Stage of Development
- 12.2.1 MAbs in Phase III Clinical Development
- 12.2.2 Mabs in Phase II Clinical Development
- 13 Appendix I: Cancer Therapeutic Antibodies in Clinical Development
- 14 Appendix II: Discontinued Projects - A Five Year Recapitulation
- 15 Appendix III: Selected Company Profiles
- 16 Disclaimer
- 17 Drug Index
- 18 Company Index
- 4.1 List of Boxes
- Box 1: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
- Box 2: Marrion’s Drug Delivery Technology
- Box 3: Quick Facts - CeaVac.
- Box 4: Quick Facts - Elsilimomab
- Box 5: Quick Facts IGN 101
- Box 6: Quick Facts IMC-BEC2
- Box 7: Quick Facts MDX 010
- Box 8: Quick Facts ONYVAX 105
- Box 9: Quick Facts - Ovare
- Box 10: Quick Facts Panitumumab
- Box 11: Quick Facts - RENCARNEX.
- Box 12: Quick Facts - Nimotuzumab
- Box 13: Quick Facts - RENCARNEX
- Box 14: Quick Facts - Lintuzumab
- Box 15: Quick Facts - Zanolimumab
- Box 16: Quick Facts ABT-510
- Box 17: Quick Facts BB 10901
- Box 18: Quick Facts CP-675206
- Box 19: Quick Facts CNTO-328
- Box 20: Quick Facts - Ecromeximab
- Box 21: Quick Facts EMD-273063
- Box 22: Quick Facts WX-G250RIT
- Box 23: Quick Facts HGS-ETR1. 97
- Box 24: Quick Facts HuMax-CD20
- Box 25: Quick Facts HuMax-EGFr2
- Box 26: Quick Facts Galiximab
- Box 27: Quick Facts PROXINIUM
- Box 28: Quick Facts RAV12
- Box 29: Quick Facts SGN-15
- Box 30: Quick Facts SGN-30
- Box 31: Quick Facts VEGF-Trap
- Box 32: Quick Facts MEDI 522
- Box 33: Quick Facts Volociximab.
- Box 34: Quick Facts Zanolimumab
- 4.2 List of Tables
- Table 1: Summary of Strategies Enhancing Antibody Function
- Table 2: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
- Table 3: Drug Delivery Companies with Cancer Focus
- Table 4: FDA Approved Polymer-based Drug Delivery Systems for Cancer
- Table 5: Antibody Therapeutics in Prostate Cance
- Table 6: Antibody Therapeutics in Breast Cancer
- Table 7: Antibody Therapeutics in Colorectal Cancer
- Table 8: Antibody Therapeutics in Melanoma
- Table 9: Antibody Therapeutics in Hematological Cancer
- Table 10: MDX-010’s Collaborative History and Landscape
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
